[1] GEORGE J, ANSTEE Q, RATZIU V, et al. NAFLD:The evolving landscape[J]. J Hepatol, 2018, 68 (2) :227-229.
|
[2] ROSSO C, MEZZABOTTA L, GAGGINI M, et al. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease[J]. Hepatology, 2016, 63 (1) :107-116.
|
[3] CHALASANI N, YOUNOSSI Z, LAVINE JE, et al. The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 67 (1) :328-357.
|
[4] ZHAO ZH, LIU XL, FAN JG. Research on the natural history of non-alcoholic fatty liver disease should be taken seriously[J]. Chin J Hepatol, 2017, 25 (2) :81-84. (in Chinese) 赵泽华, 刘晓琳, 范建高.重视非酒精性脂肪性肝病自然史的研究[J].中华肝脏病杂志, 2017, 25 (2) :81-84.
|
[5] CHAN WK, MUSTAPHA RNR, MAHADEVA S. A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis[J]. Clin Gastroenterol Hepatol, 2017, 15 (12) :1940-1949.
|
[6] LU XL, DONG L, ZHANG KX, et al. Observation on the therapeutic efficacy of silibinin capsules for patients with fatty liver disease[J]. J Pract Hepatol, 2008, 11 (6) :398-400. (in Chinese) 鲁晓岚, 董蕾, 张宽学, 等.水飞蓟宾治疗脂肪肝的疗效观察[J].实用肝脏病杂志, 2008, 11 (6) :398-400.
|
[7] MA ZQ. Clinical analysis of silibin-phosphatidylcholine treated the 61 cases alcoholicfattyliver[J]. Pract J Card Cereb Pneumal Vasc Dis, 2008, 4 (16) :29-30. (in Chinese) 马臻奇.水飞蓟宾-磷脂酰胆碱治疗酒精性脂肪肝61例临床分析[J].实用心脑肺血管病杂志, 2008, 4 (16) :29-30.
|
[8] HAJIAGHAMOHAMMADI AA, ZIAEE A, OVEISI S, et al. Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic fatty liver disease:A randomized controlled pilot study[J].Hepat Mon, 2012, 12:e6099.
|
[9] HASHEMI SJ, HAJIANI E, SARDABI EH. A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver[J]. Hepat Mon, 2009, 9:265-270.
|
[10] HUANG HX. Observation of therapeutic effects of Silibinin Capsules to treat sixty cases of nonalcoholic fatty liver disease[J].China Med Herald, 2011, 8 (7) :62-63. (in Chinese) 黄红霞.水林佳 (水飞蓟宾-磷脂复合物) 治疗非酒精性脂肪性肝病60例临床疗效观察[J].中国医药导报, 2011, 8 (7) :62-63.
|
[11] MOHESN M, AMIRMANSOOR R, MOHAMMAD P, et al. Effects of silymarin on reducing liver aminotransferases in patients with nonalcoholic fatty liver diseases[J]. Govaresh, 2013, 18 (3) :181-185.
|
[12] SOLHI H, GHAHREMANI R, KAZEMIFAR AM, et al. Silymarin in treatment of non-alcoholic steatohepatitis:A randomized clinical trial[J]. Caspian J Intern Med, 2014, 5:9-12.
|
[13] LI Y. The Clinical efficacy of silibinin and its influence to life quality of NAFLD patients[J]. Inf Tradit Chin Med, 2017, 34 (4) :88-91. (in Chinese) 李颖.水飞蓟宾治疗非酒精性脂肪性肝病的疗效分析及对患者生存质量影响的研究[J].中医药信息, 2017, 34 (4) :88-91.
|
[14] LI J. Epidemiology characteristics of nonalcoholic fatty liver disease in Asia[J]. J Clin Hepatol, 2018, 34 (12) :2515-2519. (in Chinese) 李婕.亚洲地区非酒精性脂肪性肝病的流行病学特点[J].临床肝胆病杂志, 2018, 34 (12) :2515-2519.
|
[15] GUO ZQ, WANG QY, QI XS, et al. Recommenda tions for the diagnosis and management of nonalcoholic fatty Liver disease:Practice guidance from the American Association for the Study of Liver Diseases (2017) [J]. J Clin Hepatol, 2017, 33 (12) :2275-2277. (in Chinese) 郭泽淇, 王倩怡, 祁兴顺, 等.《2017年美国肝病学会非酒精性脂肪性肝病诊疗指导》摘译[J].临床肝胆病杂志, 2017, 33 (12) :2275-2277.
|
[16] VECCHIONE G, GRASSELLI E, VOCI A, et al. Silybin counteracts lipid excess and oxidative stress in cultured steatotic hepatic cells[J]. World J Gastroenterol, 2016, 22 (26) :6016-6026.
|
[17] FENG ZM, CHENG SQ. Effects of silibinin combined with lamivudine treating the liver cirrhosis with active hepatitis B[J].Chin Gen Pract, 2007, 10 (8) :659-661. (in Chinese) 冯自明, 程书权.水飞蓟宾联合拉米夫定治疗慢性乙型肝炎活动性肝硬化疗效分析[J].中国全科医学, 2007, 10 (8) :659-661.
|
[18] LYU CJ, LI H, YANG ZF. Role of lipid metabolism in nonalcoholic fatty hepatopathy[J]. J Log Univ CAPF:Med Sci, 2013, 22 (2) :158-160. (in Chinese) 吕成娇, 李海, 杨占福.脂质代谢在非酒精性脂肪性肝病发病机制中的作用研究现状[J].武警后勤学院学报:医学版, 2013, 22 (2) :158-160.
|
[19] LI QQ, ZHOU Q, NIU JQ. New advances in pharmacological mechanism of silymarin and re-investigation of its clinical values[J]. J Clin Hepatol, 2015, 31 (2) :315-316. (in Chinese) 李青权, 周强, 牛俊奇, 等.水飞蓟素药理机制新进展及临床价值再探讨[J].临床肝胆病杂志, 2015, 31 (2) :315-316.
|
[20] HE XJ, YANG ZY, DU XL, et al. Clinical effect of Atorvastatin Calcium combined with Silibinin in the treatment of non-alcoholic fatty liver disease[J]. China Med Herald, 2017, 14 (14) :123-125, 130. (in Chinese) 贺小军, 杨振宇, 杜锡林, 等.阿托伐他汀钙联合水飞蓟宾治疗非酒精性脂肪肝的临床效果[J].中国医药导报, 2017, 14 (14) :123-125, 130.
|
[21] LIANG MX, CAI XH. Current status of pharmacokinetics and clinical study of silibinin-phospholipid complex[J]. Chin J New Drugs, 2010, 19 (19) :1778-1780. (in Chinese) 梁明欣, 蔡雪虹.水飞蓟宾-磷脂复合物的药动学及临床研究现状[J].中国新药杂志, 2010, 19 (19) :1778-1780.
|
[1] | Xiaoqing WANG, Jie LONG, Fei WANG, Zhexiong LIAN. Impact of cancer-associated fibroblasts on immunotherapy and liver metastasis in colorectal cancer[J]. Journal of Clinical Hepatology, 2024, 40(6): 1183-1190. doi: 10.12449/JCH240618 |
[2] | Rui ZHANG, Jinhong CHEN. Treatment strategy of non-radical surgical resection for colorectal cancer liver metastases[J]. Journal of Clinical Hepatology, 2024, 40(7): 1295-1300. doi: 10.12449/JCH240702 |
[3] | Chinese College of Surgeons, Chinese Medical Doctor Association, Chinese Society Gastrointestinal Surgery, Chinese Society of Surgery, Chinese Medical Association, Chinese Society of Colorectal Surgery, Chinese Society of Surgery, Chinese Medical Association, Section of Colorectal Oncology, Chinese Society of Oncology, Chinese Medical Association, Colorectal Cancer Professional Committee, Chinese Anti-Cancer Association, Colorectal Cancer Professional Committee, Chinese Medical Doctor Association, Colorectal Cancer Expert Committee, Chinese Society of Clinical Oncology, Chinese College of Colorectal Surgeons, Chinese College of Surgeons, Chinese Medical Doctor Association, Metastasis Research Committee, Anorectal Branch of Chinese Medical Doctor Association, Colorectal Liver Metastases Professional Committee, China International Exchange and Promotive Association for Medical and Health Care. China guideline for diagnosis and comprehensive treatment of colorectal liver metastases (2020 edition)[J]. Journal of Clinical Hepatology, 2021, 37(3): 543-553. doi: 10.3969/j.issn.1001-5256.2021.03.009 |
[4] | Xuemin LI, Hao WANG, Junjie WANG. Stereotactic ablative radiotherapy for colorectal cancer liver metastasis[J]. Journal of Clinical Hepatology, 2021, 37(3): 522-526. doi: 10.3969/j.issn.1001-5256.2021.03.006 |
[5] | Xiangqian HUANG, Xiaomeng YAN, Mingda ZHANG, Jing WU, Jianhong CHEN. Association between nonalcoholic fatty liver disease and colorectal neoplasms[J]. Journal of Clinical Hepatology, 2021, 37(12): 2947-2950. doi: 10.3969/j.issn.1001-5256.2021.12.045 |
[6] | Gao BenJian, Luo Jia, Liu Ying, Yang XiaoLi, Su Song, Li Bo. Efficacy and safety of laparoscopic versus open liver resection in treatment of colorectal cancer liver metastasis: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(3): 573-579. doi: 10.3969/j.issn.1001-5256.2020.03.021 |
[7] | Li Jiang, Hou Yu, Cai XiaoBei, Xu ChengLei, Yi GenFa. Clinical effect of local treatment based on limited segmental resection in improving the prognosis of liver oligometastasis after surgery for colorectal cancer[J]. Journal of Clinical Hepatology, 2020, 36(8): 1763-1767. doi: 10.3969/j.issn.1001-5256.2020.08.017 |
[8] | Liao Yang, Li ShengWei. Current status of associating liver partition and portal vein ligation for staged hepatectomy in treatment of liver metastasis of colorectal cancer[J]. Journal of Clinical Hepatology, 2019, 35(12): 2805-2808. doi: 10.3969/j.issn.1001-5256.2019.12.035 |
[9] | Liu SiFu, Xie ZhengYuan. Association between nonalcoholic fatty liver disease and colorectal tumors[J]. Journal of Clinical Hepatology, 2019, 35(9): 2091-2094. doi: 10.3969/j.issn.1001-5256.2019.09.046 |
[10] | Min YongFeng, Zhang Bo. Microwave ablation combined with 125I particle implantation in treatment of hepatic metastasis with diaphragm perforation: A case report[J]. Journal of Clinical Hepatology, 2018, 34(8): 1758-1759. doi: 10.3969/j.issn.1001-5256.2018.08.034 |
[11] | Li Hao, Duan XuHua, Han XinWei, Ren JianZhuang, Li FengYao, Kuang DongLin, Li FangZheng. Clinical effect of transarterial chemoembolization combined with radiofrequency ablation in treatment of rabbit VX2 liver tumors[J]. Journal of Clinical Hepatology, 2018, 34(4): 779-783. doi: 10.3969/j.issn.1001-5256.2018.04.017 |
[12] | Sun Wei, Ding XiaoYan, Chen JingLong, Li WenDong, Guo XiaoDi, Shen YanJun, Sun ShaSha, Teng Ying, Liu XiaoMin, Wei JianYing. Clinical effect and safety of radiofrequency ablation combined with systemic chemotherapy in treatment of unresectable or postoperative recurrent intrahepatic cholangiocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(8): 1717-1722. doi: 10.3969/j.issn.1001-5256.2018.08.025 |
[13] | Society for Minimally Invasive Surgery, Chinese Research Hospital Association. Technical guidelines for simultaneous laparoscopic and robotic resection of colorectal cancer with liver metastasis ( Revised in 2017)[J]. Journal of Clinical Hepatology, 2018, 34(3): 494-497. doi: 10.3969/j.issn.1001-5256.2018.03.007 |
[14] | An DongJun, An Lin, Zhang Cheng, Zhao WeiAn, Han Li. Efficacy of laparoscopic microwave ablation in treatment of malignant liver tumors[J]. Journal of Clinical Hepatology, 2017, 33(11): 2158-2161. doi: 10.3969/j.issn.1001-5256.2017.11.021 |
[15] | Song Li, Zou YingHua. Prevention and treatment of complications after radiofrequency ablation for hepatic tumors in high-risk locations[J]. Journal of Clinical Hepatology, 2017, 33(4): 647-650. doi: 10.3969/j.issn.1001-5256.2017.04.009 |
[16] | Lu NingNing, Sun Bin, Cui XiongWei, Long Jiang, Gao WenFeng, Zheng JiaSheng. Diagnosis and treatment of subcapsular hemorrhage after liver tumor ablation[J]. Journal of Clinical Hepatology, 2017, 33(12): 2326-2330. doi: 10.3969/j.issn.1001-5256.2017.12.014 |
[17] | Wang DongXu, Huo TingTing, Tian YaoWen, Zhao Lei. Current status of research on microRNA associated with colorectal cancer liver metastasis[J]. Journal of Clinical Hepatology, 2016, 32(12): 2387-2390. doi: 10.3969/j.issn.1001-5256.2016.12.034 |
[18] | Jian QianHong, Zheng FangRong, Yan Xiong. Current status of research on transcatheter arterial chemoembolization in treatment of colorectal cancer liver metastasis[J]. Journal of Clinical Hepatology, 2016, 32(6): 1216-1219. doi: 10.3969/j.issn.1001-5256.2016.06.047 |
[19] | Wang Xin, Zhang Hui, He XiaoJun, Li XinHui, Liu Yang, Zhang HongYi. Clinical effect of precise sequential interventional therapy in patients with unresectable hepatic metastasis after surgery for colorectal cancer[J]. Journal of Clinical Hepatology, 2016, 32(3): 518-521. doi: 10.3969/j.issn.1001-5256.2016.03.025 |
[20] | Zhang ZhiQuan. Analysis of prognostic factors for patients treated by radical resection of liver metastases from colorectal cancer[J]. Journal of Clinical Hepatology, 2015, 31(9): 1455-1457. doi: 10.3969/j.issn.1001-5256.2015.09.022 |
1. | 凌清儿,张戎. 肝纤维化治疗的研究进展. 现代医药卫生. 2023(11): 1926-1931 . ![]() | |
2. | 揭阳,叶林茂,何怡,邵畅,孙希光,张俊杰. 基于IFN-γ/STAT1/Smad7通路探讨疏肝健脾活血方抗肝纤维化作用机制. 中华中医药杂志. 2023(09): 4136-4141 . ![]() |